Shohei Ohtani signs lifetime deal with New Balance
Summarised from 2 outlets · Updated 20 Nov, 19:38 · Archive
Shohei Ohtani has agreed to a career-long endorsement contract with New Balance.
Shohei Ohtani has agreed to a lifetime endorsement contract with New Balance that will extend through the remainder of his playing career. The deal, announced on Friday, is believed to be the first such career-long sponsorship for a baseball player, putting Ohtani alongside superstar athletes like LeBron James and Cristiano Ronaldo who have similar lifetime deals with Nike and Damian Lillard with Adidas.
Ohtani signed with New Balance in 2023, the same year he joined the Los Angeles Dodgers on a 10-year, $700 million contract. He has worn New Balance gloves and cleats and has his own line of apparel with the company, featuring a custom logo. He has been prominently featured in the brand's television commercials and marketing campaigns.
As part of the extended deal, New Balance has renamed its Sports Research Lab at its Boston headquarters after Ohtani in recognition of his contributions to athlete research, innovation and product development. Ohtani told GQ that the relationship is built on trust and that New Balance has accommodated his requests for changes to footwear and apparel. The deal has also expanded New Balance's presence in Japan, Ohtani's native country.

How it is being reported
- New Balance Renames Research Lab After Shohei Ohtani, Extends Superstar's ContractShohei Ohtani and New Balance have extended their contract for the rest of his playing career.Fox News · 20 Nov, 18:24
- Shohei Ohtani signs lifetime deal with New Balance, plans changes to cleatsShohei Ohtani has joined rarified air with his new endorsement dealNew York Post · 20 Nov, 17:44
In this story: Shohei Ohtani · New Balance · Los Angeles Dodgers · Boston · Japan
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log
Comments (0)